Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C15H10BrClN2O2 |
| Molecular Weight | 365.609 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1N=C(C2=CC=CC=C2Cl)C3=CC(Br)=CC=C3NC1=O
InChI
InChIKey=KRJKJUWAZOWXNV-UHFFFAOYSA-N
InChI=1S/C15H10BrClN2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Spectral changes in the liver microsomal cytochrome P-450 of rats during interaction with phenazepam and its 3-hydroxy metabolite]. | 1984 Aug |
|
| Biokinetics of transdermal 3-hydroxyphenazepam. | 2002 Sep |
|
| [Peculiarities of hypnotic effect and pharmacokinetics of hemisuccinate 3-hydroxyphenazepam (levana)]. | 2014 |
|
| [Kinetics of hydrolysis of 1,4-benzodiazepine derivative by carboxylesterases in mice organism]. | 2014 Jul-Aug |
|
| Analysis of phenazepam and 3-hydroxyphenazepam in post-mortem fluids and tissues. | 2015 Oct |
|
| Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam. | 2016 Nov |
|
| Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. | 2017 Apr |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-3-Hydroxyphenazepam
Created by
admin on Sat Dec 16 10:19:24 GMT 2023 , Edited by admin on Sat Dec 16 10:19:24 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000175980
Created by
admin on Sat Dec 16 10:19:24 GMT 2023 , Edited by admin on Sat Dec 16 10:19:24 GMT 2023
|
PRIMARY | |||
|
1KJ8MP77JK
Created by
admin on Sat Dec 16 10:19:24 GMT 2023 , Edited by admin on Sat Dec 16 10:19:24 GMT 2023
|
PRIMARY | |||
|
70030-11-4
Created by
admin on Sat Dec 16 10:19:24 GMT 2023 , Edited by admin on Sat Dec 16 10:19:24 GMT 2023
|
PRIMARY | |||
|
125820
Created by
admin on Sat Dec 16 10:19:24 GMT 2023 , Edited by admin on Sat Dec 16 10:19:24 GMT 2023
|
PRIMARY | |||
|
3-HYDROXYPHENAZEPAM
Created by
admin on Sat Dec 16 10:19:24 GMT 2023 , Edited by admin on Sat Dec 16 10:19:24 GMT 2023
|
PRIMARY | Novel benzodiazepine, 3-Hydroxyphenazepam | ||
|
3-HYDROXYPHENAZEPAM
Created by
admin on Sat Dec 16 10:19:24 GMT 2023 , Edited by admin on Sat Dec 16 10:19:24 GMT 2023
|
PRIMARY | 3-Hydroxyphenazepam is a benzodiazepine with hypnotic, sedative, anxiolytic, and anticonvulsant properties. It is an active metabolite of phenazepam, as well as the active metabolite of the benzodiazepine prodrug cinazepam. Relative to phenazepam, 3-hydroxyphenazepam has diminished myorelaxant properties, but is about equivalent in most other regards. Like other benzodiazepines, 3-hydroxyphenazepam behaves as a positive allosteric modulator of the benzodiazepine site of the GABAA receptor. It has been sold online as a designer drug. | ||
|
DTXSID10990281
Created by
admin on Sat Dec 16 10:19:24 GMT 2023 , Edited by admin on Sat Dec 16 10:19:24 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE ACTIVE)
